source
- aTyr Pharma cuts 60% of staff to fund second phase 3 trial of lung disease drug efzofitimodaTyr Pharma announced it will reduce its workforce by about 60%, leaving roughly 20 employees, to reallocate resources toward its lung disease program. The cut follows the company's previous phase…
- Latigo and BlossomHill file Nasdaq IPO plans to fund pain and cancer pipelinesLatigo Biotherapeutics and BlossomHill Therapeutics, both based in California, have filed applications to list on the Nasdaq Global Select Market. Latigo aims to raise up to $285.2 million to advan…